Recent advances and challenges in antibacterial drug development.
作者信息
Gigante Valeria, Sati Hatim, Beyer Peter
机构信息
Impact Initiatives and Research Coordination Unit, Global Coordination Department, AMR Division, WHO, Geneva, Switzerland.
出版信息
ADMET DMPK. 2022 Mar 4;10(2):147-151. doi: 10.5599/admet.1271. eCollection 2022.
Abstract
摘要
相似文献
1
Recent advances and challenges in antibacterial drug development.抗菌药物研发的最新进展与挑战
ADMET DMPK. 2022 Mar 4;10(2):147-151. doi: 10.5599/admet.1271. eCollection 2022.
2
The antibiotic pipeline: reviving research and development and speeding drugs to market.抗生素研发渠道：重振研发并加速药物上市
Expert Rev Anti Infect Ther. 2017 May;15(5):425-433. doi: 10.1080/14787210.2017.1308251. Epub 2017 Mar 29.
3
Evaluating the innovative potential of the global antibacterial pipeline.评估全球抗菌药物研发产品线的创新潜力。
Clin Microbiol Infect. 2025 Jun;31(6):903-909. doi: 10.1016/j.cmi.2023.09.024. Epub 2023 Oct 5.
4
Recent Advances in the Development of Lipid-, Metal-, Carbon-, and Polymer-Based Nanomaterials for Antibacterial Applications.用于抗菌应用的脂质基、金属基、碳基和聚合物基纳米材料开发的最新进展
Nanomaterials (Basel). 2022 Nov 1;12(21):3855. doi: 10.3390/nano12213855.
5
Advances of peptides for antibacterial applications.肽在抗菌应用中的进展。
Colloids Surf B Biointerfaces. 2021 Jun;202:111682. doi: 10.1016/j.colsurfb.2021.111682. Epub 2021 Mar 8.
6
Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials.对抗抗生素耐药性——寻找新抗菌药物的策略和（临床前）研发。
EMBO Rep. 2023 Jan 9;24(1):e56033. doi: 10.15252/embr.202256033. Epub 2022 Dec 19.
7
Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.应对抗生素研发中的紧迫优先事项：来自世界卫生组织2023年抗菌药物临床研发管线分析的见解
Lancet Microbe. 2025 Mar;6(3):100992. doi: 10.1016/j.lanmic.2024.100992. Epub 2024 Oct 22.
8
Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.全球临床前抗菌药物研发管道的多年分析：趋势与差距。
Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0053524. doi: 10.1128/aac.00535-24. Epub 2024 Jul 15.
9
The global need for effective antibiotics: challenges and recent advances.全球对抗生素的有效需求：挑战与最新进展。
Trends Pharmacol Sci. 2010 Nov;31(11):509-15. doi: 10.1016/j.tips.2010.08.002. Epub 2010 Sep 16.
10
Designing antibacterial materials through simulation and theory.通过模拟和理论设计抗菌材料。
J Mater Chem B. 2024 Sep 25;12(37):9155-9172. doi: 10.1039/d4tb01277a.
引用本文的文献
1
In Vitro synergy of Farnesyltransferase inhibitors in combination with colistin against ESKAPE bacteria.法尼基转移酶抑制剂与黏菌素联合对ESKAPE细菌的体外协同作用
PLoS One. 2025 Sep 5;20(9):e0331440. doi: 10.1371/journal.pone.0331440. eCollection 2025.
2
Structural Insights into the Protein Mannosyltransferase from Mycobacterium tuberculosis reveal a WW-Domain-Like Protein Motif in Bacteria.结核分枝杆菌蛋白甘露糖基转移酶的结构洞察揭示了细菌中一种类似WW结构域的蛋白基序
Commun Biol. 2025 Aug 7;8(1):1175. doi: 10.1038/s42003-025-08593-9.
3
Exploring the Biodiversity and Antibacterial Potential of the Culturable Soil Fungi in Nyingchi, Tibet.探索西藏林芝可培养土壤真菌的生物多样性及抗菌潜力。
J Fungi (Basel). 2025 Apr 1;11(4):276. doi: 10.3390/jof11040276.
4
A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges.对抗多重耐药菌的抗菌药物综合概述：现状、发展、未来机遇与挑战
Antibiotics (Basel). 2025 Feb 21;14(3):221. doi: 10.3390/antibiotics14030221.
5
Hollow Fiber Microreactor Combined with Digital Twin to Optimize the Antimicrobial Evaluation Process.中空纤维微反应器结合数字孪生技术优化抗菌评估过程。
Micromachines (Basel). 2024 Dec 20;15(12):1517. doi: 10.3390/mi15121517.
6
New Agents Are Coming, and So Is the Resistance.新的病原体正在出现，耐药性问题也随之而来。
Antibiotics (Basel). 2024 Jul 13;13(7):648. doi: 10.3390/antibiotics13070648.
7
as an In Vivo Model for the Discovery and Development of Natural Plant-Based Antimicrobial Compounds.作为天然植物源抗菌化合物发现与开发的体内模型。
Pharmaceuticals (Basel). 2023 Jul 27;16(8):1070. doi: 10.3390/ph16081070.
8
Alternate Antimicrobial Therapies and Their Companion Tests.替代抗菌疗法及其配套检测
Diagnostics (Basel). 2023 Jul 26;13(15):2490. doi: 10.3390/diagnostics13152490.
9
Recent Advances in Pharmaceutical Approaches of Antimicrobial Agents for Selective Delivery in Various Administration Routes.抗菌药物在不同给药途径中实现选择性递送的药学方法的最新进展
Antibiotics (Basel). 2023 Apr 27;12(5):822. doi: 10.3390/antibiotics12050822.
10
Metagenomic-based surveillance systems for antibiotic resistance in non-clinical settings.非临床环境中基于宏基因组学的抗生素耐药性监测系统。
Front Microbiol. 2022 Dec 2;13:1066995. doi: 10.3389/fmicb.2022.1066995. eCollection 2022.
本文引用的文献
1
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.2019 年全球细菌对抗菌药物耐药性的负担：系统分析。
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
2
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed.分析治疗耐药菌感染的临床药物研发管线：尽管取得了进展，但仍需采取更多行动。
Antimicrob Agents Chemother. 2022 Mar 15;66(3):e0199121. doi: 10.1128/AAC.01991-21. Epub 2022 Jan 10.
3
Designing development programs for non-traditional antibacterial agents.设计非传统抗菌药物的开发项目。
Nat Commun. 2019 Jul 31;10(1):3416. doi: 10.1038/s41467-019-11303-9.
4
Non-traditional Antibacterial Therapeutic Options and Challenges.非传统抗菌治疗选择与挑战。
Cell Host Microbe. 2019 Jul 10;26(1):61-72. doi: 10.1016/j.chom.2019.06.004.
5
Classifying antibiotics in the WHO Essential Medicines List for optimal use-be AWaRe.对世界卫生组织基本药物清单中的抗生素进行分类以实现最佳使用——采用“明智用药”原则。
Lancet Infect Dis. 2018 Jan;18(1):18-20. doi: 10.1016/S1473-3099(17)30724-7. Epub 2017 Dec 20.
6
Challenges and Opportunities of Nontraditional Approaches to Treating Bacterial Infections.非传统方法治疗细菌感染的挑战与机遇。
Clin Infect Dis. 2017 Aug 1;65(3):495-500. doi: 10.1093/cid/cix320.
Zotero 插件